STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology
April 29 2014 - 10:45AM
Business Wire
STENTYS highlighted as a solution to
minimize stent malapposition in clinical practice
Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical
technology company commercializing the world’s first and only
Self-Apposing® Stent for treating acute myocardial infarction
(AMI), today announced that the Journal of the American College of
Cardiology (JACC) published a “State-of-the-Art Paper” entitled
“Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete
Stent Apposition,” which highlights STENTYS’ Self-Apposing Stent
among novel devices to minimize stent malapposition, also known as
incomplete stent apposition (ISA), in clinical practice.
According to the authors: “Some particular clinical scenarios
such as acute coronary syndromes, bifurcations, tapered vessels,
overlapping stents, and chronic total occlusions might predispose
to ISA. Interventional cardiologists should be committed to optimal
stent choices and techniques of implantation and use intravascular
imaging guidance when appropriate to aim at minimizing acute
ISA.”
The authors advise that novel devices, such as STENTYS’
Self-Apposing stent, which already demonstrated an early reduction
of ISA compared with balloon-expandable stents during primary PCI,
can reduce malapposition and the potentially harmful consequences
with which it is associated.
Gonzague Issenmann, co-founder and Chief Executive Officer of
STENTYS said: “Malapposition continues to be a challenge for
cardiologists, particularly when vessel diameter is ambiguous or
fluctuating, as in the post-infarction phase. We are pleased that
JACC and the authors provided such a detailed discussion of this
issue and its dreadful consequences for patients, and that our
Self-Apposing Stent technology was highlighted as a solution to
malapposition.”
References: Mechanisms, Pathophysiology, and Clinical Aspects of
Incomplete Stent Apposition. Attizzani, et al. J. Am. Coll.
Cardiol. 2014; 63(14):1355-1367. Article published in the April 15,
2014 issue.
About the STENTYS Self-Apposing® StentThe
STENTYS Self-Apposing® Stent addresses the stent-sizing dilemma
that cardiologists are confronted with when treating heart attack
patients or patients with atypical artery anatomy. Its flexible,
self expanding design takes the shape of the patient’s unique
vessel anatomy and apposes to the irregular contours of a blood
vessel, in particular after an AMI as the vessel dilates and the
clot dissolves. It reduces the risk of malapposition and
complications associated with conventional stents in this setting.
The STENTYS Self-Apposing Stent has been marketed in Europe since
receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent
should receive the CE Mark during the second half of 2014.
About STENTYSSTENTYS is developing and commercializing
innovative solutions for the treatment of patients with acute
myocardial infarction (AMI, or heart attack) and complex coronary
artery disease. STENTYS’ Self-Apposing® Stents are designed to
adapt to vessels with ambiguous or fluctuating diameters,
particularly in the post-infarction phase, in order to prevent the
malapposition problems associated with conventional stents. In the
APPOSITION III clinical trial, STENTYS stents demonstrated a very
low one year mortality rate among 1,000 high-risk AMI patients when
compared to recent studies with conventional stents. More
information is available at www.stentys.com.
This press release contains forward looking statements about the
Company’s business. Such forward looking statements are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which it will operate in
the future which may not be accurate. Such forward-looking
statements involve known and unknown risks which may cause the
Company’s actual results, performance or achievements to differ
materially from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such
factors include, among others, risks associated with the
development and commercialization of the Company’s products, market
acceptance of the Company’s products, its ability to manage growth,
the competitive environment in relation to its business area and
markets, its ability to enforce and protect its patents and
proprietary rights, uncertainties related to the U.S. FDA approval
process, including with respect to a pre-market approval for the
Company’s BMS, slower than expected rates of patient recruitment
for clinical trials, the outcome of clinical trials, and other
factors, including those described in the Section 4 “Risk Factors”
of the Company’s 2011 Registration Document (document de référence)
filed with the French Autorité des Marchés Financiers on August 27,
2013 under number R.13-040 as such section may be updated from time
to time.
STENTYS is listed on Comp. B of the NYSE Euronext ParisISIN:
FR0010949404 – Ticker: STNT
STENTYSStanislas PiotCFOTel.: +33 (0)1 44 53 99
42stan.p@stentys.comorNewCap.Financial Communication /
Investor RelationsDusan Oresansky / Pierre LaurentTel.: +33 (0)1 44
71 94 93stentys@newcap.frorUS: MacDougall Biomedical
CommunicationsCharles Liles, Tel.: 781 235 3060Christine
Labaree or Hunter Marshall, Tel.: 650 339
7533stentys@macbiocom.com
Stevia Nutra (CE) (USOTC:STNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Stevia Nutra (CE) (USOTC:STNT)
Historical Stock Chart
From Jul 2023 to Jul 2024
